Yesterday’s report framed ATRA around a PDUFA-window setup, with the assumption that the 2025 CRL was primarily a CMC/GMP story and that the ALLELE trial remained acceptable as the pivotal efficacy dataset. Today that premise is broken: the FDA has issued a second Complete Response Letter (CRL) for tabelecleucel/tab-cel in EBV+ PTLD.